ZYBERNO
Stock Report
Updated Aug 31, 2026

Biohaven Ltd. (BHVN)

Healthcare • NYSE

$15.41

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
Biohaven Ltd. (BHVN) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,328.9%)
Debt-to-Equity (Solvency Risk):CRITICAL (3.12x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-320.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Biohaven Ltd. (BHVN) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BHVN generated -$594.49M in Owner Earnings. Capital was deployed as follows: $254.00K invested in capital expenditures. Reinvestment rate: 2.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:15.41
Market Cap:$2.32B

Valuation Multiples (2)

P/B Ratio:189.93x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.12B

Price Action & Momentum (3)

Momentum Percentile:46 / 100
% of 52-Week High:83.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-138.3%
Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-6.9%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$29.46
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:52.1%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.73x
Quick Ratio:4.73x
Cash Ratio:3.80x

Leverage Analysis (3)

Debt To Equity Ttm:3.12x
Debt-to-Equity Ratio:3.12x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:233,901,000.00
Cash And Cash Equivalents:238,033,000.00
Long Term Debt:$32.89M
Net Debt:-$200.48M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$567.44M

Bottom Line Performance (3)

-$586.84M
Income Before Tax:-$585.61M
Ebitda Ttm:-558,758,000.00

Operating Expenses (5)

Operating Expenses:567,443,000.00
R And D Expense:467,755,000.00
Sga Expense:99,688,000.00
Income Tax Expense:$1.24M
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$370.74M
Current Assets:$296.56M
Ppe Net:15,089,000.00
Goodwill:1,390,000.00
Intangible Assets:$18.40M

Liability Structure (4)

Total Liabilities:358,517,000.00
Current Liabilities:62,658,000.00
Long Term Debt:$32.89M
Short Term Debt:$4.67M

Equity & Capital (3)

Equity:$12.22M
Retained Earnings:-$2.35B
Common Stock:2,138,861,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:50,544,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:19,164,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$594.23M-$594.49M

Investment Activities (2)

Investing Cash Flow:$15.21M
Capital Expenditures Ttm:254,000.00

Financing Activities (3)

Financing Cash Flow:$179.02M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:178,884,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:8,685,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.54
-$4.54
Earnings Per Share Ttm:-$3.90

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$4.05

Book Value & Capital (2)

Book Value Per Share:$0.08
Cash Per Share:1.58

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$594.49M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-6.9%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-40.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:BHVN
Company Name:Biohaven Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:150.64M
Shares Outstanding Basic:150.64M
Shares Outstanding Diluted:150.64M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 12:58:19 UTC
Data Timestamp:2026-08-31T12:58:19.856957
Scroll to Top